Connection

Co-Authors

This is a "connection" page, showing publications co-authored by CATHY ENG and EDMUND SCOTT KOPETZ.
Connection Strength

1.799
  1. Commentary: practice patterns and potential impact on quality measures for a practicing physician. J Oncol Pract. 2009 Sep; 5(5):233-5.
    View in: PubMed
    Score: 0.349
  2. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20; 26(12):2000-5.
    View in: PubMed
    Score: 0.318
  3. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
    View in: PubMed
    Score: 0.122
  4. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117.
    View in: PubMed
    Score: 0.116
  5. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer. 2012 Sep; 11(3):191-4.
    View in: PubMed
    Score: 0.103
  6. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010 May 20; 28(15):2549-55.
    View in: PubMed
    Score: 0.091
  7. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
    View in: PubMed
    Score: 0.089
  8. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 01; 27(22):3677-83.
    View in: PubMed
    Score: 0.086
  9. Emerging drugs for colorectal cancer. Expert Opin Emerg Drugs. 2008 Dec; 13(4):629-42.
    View in: PubMed
    Score: 0.083
  10. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer. 2008 Jan; 7(1):55-9.
    View in: PubMed
    Score: 0.078
  11. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188.
    View in: PubMed
    Score: 0.038
  12. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015 Feb 03; 112(3):424-8.
    View in: PubMed
    Score: 0.032
  13. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol. 2014 Oct; 25(10):2008-2014.
    View in: PubMed
    Score: 0.031
  14. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer. 2014 Apr 15; 120(8):1162-70.
    View in: PubMed
    Score: 0.030
  15. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):301-5.
    View in: PubMed
    Score: 0.029
  16. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013 Dec 15; 119(24):4231-41.
    View in: PubMed
    Score: 0.029
  17. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis. 2012 Jul; 33(7):1327-31.
    View in: PubMed
    Score: 0.026
  18. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011 Mar 10; 29(8):1083-90.
    View in: PubMed
    Score: 0.024
  19. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol. 2010 Nov; 17(11):2863-9.
    View in: PubMed
    Score: 0.023
  20. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 01; 27(16):2598-603.
    View in: PubMed
    Score: 0.021
  21. Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):818-23.
    View in: PubMed
    Score: 0.021
  22. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
    View in: PubMed
    Score: 0.021
  23. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer. 2008 Sep; 7(5):338-42.
    View in: PubMed
    Score: 0.020
  24. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg. 2007 Nov; 11(11):1498-504; discussion 1504-5.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.